Cullinan Therapeutics, Inc.
CGEM
$8.71
$0.202.35%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 14.56M | 13.35M | 13.77M | 12.34M | 10.64M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 55.05M | 48.86M | 50.03M | 42.99M | 45.49M |
| Operating Income | -55.05M | -48.86M | -50.03M | -42.99M | -45.49M |
| Income Before Tax | -47.53M | -40.56M | -42.03M | -37.34M | -39.69M |
| Income Tax Expenses | 117.00K | -- | -- | -- | -14.12M |
| Earnings from Continuing Operations | -47.65M | -40.56M | -42.03M | -37.34M | -25.56M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 0.00 | -- | -- | 192.00K | 1.76M |
| Net Income | -47.65M | -40.56M | -42.03M | -37.15M | -23.80M |
| EBIT | -55.05M | -48.86M | -50.03M | -42.99M | -45.49M |
| EBITDA | -54.97M | -48.78M | -49.95M | -42.91M | -45.41M |
| EPS Basic | -0.81 | -0.70 | -0.76 | -0.86 | -0.56 |
| Normalized Basic EPS | -0.51 | -0.43 | -0.48 | -0.54 | -0.54 |
| EPS Diluted | -0.81 | -0.70 | -0.76 | -0.86 | -0.56 |
| Normalized Diluted EPS | -0.51 | -0.43 | -0.48 | -0.54 | -0.54 |
| Average Basic Shares Outstanding | 58.58M | 58.34M | 55.05M | 43.01M | 42.79M |
| Average Diluted Shares Outstanding | 58.58M | 58.34M | 55.05M | 43.01M | 42.79M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
